# The Effect of Hepatitis B Infection on Levels of Fibrinogen, Protein C, and Protein S in Pregnant Women

**Authors:** Abiba Alhassan Khalifah, Stephen Twumasi, Allwell Adofo Ayirebi, Wina Ivy Ofori Boadu, Francis Agyei Amponsah, Joseph Frimpong, David Amoah Afrifah, Ernest Appiagyei, Albert Ntim Boadu, Daniel Nii Martey Antonio, Enoch Odame Anto

PMC · DOI: 10.1155/jp/5239969 · Journal of Pregnancy · 2026-03-08

## TL;DR

This study finds that pregnant women with hepatitis B have lower levels of key coagulation factors and higher liver enzyme levels compared to uninfected pregnant women.

## Contribution

The study identifies fibrinogen, protein C, and aPTT as potential diagnostic indicators for chronic hepatitis B in pregnant women.

## Key findings

- Hepatitis B-positive pregnant women had significantly lower levels of fibrinogen, protein C, and protein S compared to controls.
- Higher AST, ALP, and bilirubin levels were observed in hepatitis B-positive pregnant women.
- aPTT showed the highest diagnostic accuracy (AUC = 0.881) for detecting chronic hepatitis B in pregnant women.

## Abstract

Viral hepatitis has been associated with profound alterations in the coagulation system as well as liver biomarkers. Meanwhile, during pregnancy, the coagulation system also undergoes significant changes with an increase in the majority of the clotting factors and a decrease in natural anticoagulants. This study is aimed at evaluating the coagulation profile and liver biomarkers among hepatitis B‐infected pregnant women in a Ghanaian population.

This case–control study was conducted at Afrancho Polyclinic in the Ashanti Region, Ghana from January 2022 to July 2023. This study recruited 90 hepatitis B pregnant women as cases and 90 hepatitis B‐negative pregnant women as controls. A structured questionnaire was used to obtain sociodemographic, obstetric, and clinical data from each participant.

Levels of albumin, fibrinogen (4.09 [3.57–5.94] vs. 6.89 [5.43–9.08], p < 0.0001), protein C (2.46 [1.09–3.42] vs. 4.12 [2.96–6.07], p < 0.0001), and protein S (2.61 [2.20–3.36] vs. 2.98 [2.53–3.54], p = 0.036) were significantly reduced in the hepatitis B‐positive pregnant women than the negative controls. However, there were higher levels of AST, ALP, and bilirubins in hepatitis B‐positive pregnant women than the controls. Also, protein C and protein S had a significantly positive association with PT and aPTT, whereby a rise in protein C and protein S resulted in an increasing PT and aPTT, respectively (all p values < 0.05). Conversely, albumin had a negative correlation with both PT and aPTT (p value < 0.05). In a ROC analysis, aPTT had the highest area under the curve (AUC) value (AUC = 0.881) and the optimal clotting time at which aPTT indicated chronic hepatitis B was ≥ 35.7 s with sensitivity of 79.4% and specificity of 91.6%.

Pregnant women with hepatitis B infection present with significant changes in their coagulation parameters, natural anticoagulants, and liver biomarkers. Furthermore, fibrinogen, protein C, and aPTT showed accurate diagnostic potential in detecting chronic viral hepatitis B infection and may be valuable surrogate indicators for managing chronic hepatitis‐related complications.

## Linked entities

- **Proteins:** FGB (fibrinogen beta chain)
- **Diseases:** Hepatitis B (MONDO:0005344)

## Full-text entities

- **Genes:** GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, PROC (protein C, inactivator of coagulation factors Va and VIIIa) [NCBI Gene 5624] {aka APC, PC, PROC1, THPH3, THPH4}, GGTLC4P (gamma-glutamyltransferase light chain 4 pseudogene) [NCBI Gene 729838] {aka GGT}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, ATHS (atherosclerosis susceptibility (lipoprotein associated)) [NCBI Gene 470] {aka ALP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, LIX1 (limb and CNS expressed 1) [NCBI Gene 167410] {aka C5orf11, Lft}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, PLAT (plasminogen activator, tissue type) [NCBI Gene 5327] {aka T-PA, TPA}, G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, SERPINC1 (serpin family C member 1) [NCBI Gene 462] {aka AT3, AT3D, ATIII, ATIII-R2, ATIII-T1, ATIII-T2}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** dysfibrinogenemia (MESH:C562727), hypercoagulable (MESH:D019851), aPTT (MESH:C000719197), bleeding (MESH:D006470), hemostatic abnormalities (MESH:D020141), inflammation (MESH:D007249), chronic hepatitis-related complications (MESH:D008107), chronic hepatitis (MESH:D006521), Fibrosis (MESH:D005355), liver fibrosis (MESH:D008103), preeclampsia (MESH:D011225), Hepatitis B Infection (MESH:D006509), cancer (MESH:D009369), diabetes mellitus (MESH:D003920), Acute and Chronic Hepatitis B Infection (MESH:D019694), hepatic injury (MESH:D056486), tuberculosis (MESH:D014376), liver (MESH:D017093), DVT (OMIM:612862), PT (MESH:D007020), hepatocellular carcinoma (MESH:D006528), venous thromboembolism (MESH:D054556), death (MESH:D003643), HBV-infected (MESH:D014777), thrombosis (MESH:D013927), PT (MESH:D006526), deep vein thrombosis (MESH:D020246), cerebrovascular disorders (MESH:D002561), cardiovascular diseases (MESH:D002318), coagulation (MESH:D001778), infected (MESH:D007239), chronic viral hepatitis (MESH:D006525), thrombocytopenia (MESH:D013921)
- **Chemicals:** bilirubin (MESH:D001663), EDTA (MESH:D004492), Alcohol (MESH:D000438), herbal remedies (-)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Hepatitis B virus (no rank) [taxon 10407], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968073/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12968073/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968073/full.md

---
Source: https://tomesphere.com/paper/PMC12968073